ArticleCurrent pharmaceutical design2026

Loss of CD99L2 Contributed to Temozolomide Resistance and Glioblastoma Tumorigenesis Based on Genome-scale CRISPR/Cas9 Screening.

Zeen Sun et al.PubMed ↗Publisher ↗

No numbers read from the abstract.